House passes 21st Century Cures Act; Omeros snags EU recommendation for Omidria;

@FierceBiotech: Amgen's PCSK9 contender lines up for first place in the blockbuster EU race. Story | Follow @FierceBiotech

@JohnCFierce: What's your list of top 5 public biotechs? (Potential, management, smart execution) I'd put $BLUE in that group. Any other suggestions? | Follow @JohnCFierce

> The U.S. House of Representatives signed off on the the 21st Century Cures Act, a bill designed to speed the path of new medicines by increasing funding to the FDA and NIH. Story

> The European Medicines Agency's Committee for Medicinal Products for Human Use recommended Omeros' eye drug ($OMER) Omidria for approval. News

> GlaxoSmithKline ($GSK) submitted its asthma antibody mepolizumab for Japanese approval. More

Medical Device News

@FierceMedDev: Neuwave Medical reels in $25M for minimally invasive ablation device. Story | Follow @FierceMedDev

@VarunSaxena2: Issue that led to halt of St. Jude TAVR trial no cause for concern, EuroPCR experts say $STJ. More | Follow @VarunSaxena2

@EmilyWFierce: $MDT CEO Omar Ishrak on the company's strategy in #India: Article | Follow @EmilyWFierce

> India developing federal medical device surveillance system. News

> Report: Researchers develop neuron chips to direct movement of robotic prosthetics. More

Pharma News

@FiercePharma: Chicken producer Sanderson says FDA's crackdown on antibiotics lacks 'reliable science.' Article | Follow @FiercePharma

@EricPFierce: #FDA blesses Baxter #saline plant in Spain for shipments to U.S. of  0.9% sodium chloride. More | Follow @EricPFierce

@CarlyHFierce: #ICYMI yesterday - Report: Cadila next in line for injectables bulk-up as it nears deal for Claris. Story | Follow @CarlyHFierce

> Celgene's next-gen psoriasis drug dissed by German cost watchdog. News

> England's Cancer Drugs Fund keeps Bayer's Stivarga, axes Eisai and Lilly meds. More

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.